<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2020000200049</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.19000289</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Sorafenib use in patients with radioiodine-refractory differentiated thyroid cancer &#8211; A five-year experience at the ISSSTE National Medical Center 20 de Noviembre in Mexico City]]></article-title>
<article-title xml:lang="es"><![CDATA[Uso de sorafenib en pacientes con cáncer de tiroides diferenciado refractario al yodo: una experiencia de cinco años en el ISSSTE Centro Médico Nacional 20 de Noviembre en la Ciudad de México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Juárez-Ramiro]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gurrola-Machuca]]></surname>
<given-names><![CDATA[Héctor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villavicencio-Quejeiro]]></surname>
<given-names><![CDATA[Michael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Núñez-Guajardo]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salazar-Andrade]]></surname>
<given-names><![CDATA[Jorge A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Erazo-Valle Solís]]></surname>
<given-names><![CDATA[Aura A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cervantes-Sánchez]]></surname>
<given-names><![CDATA[María G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Loya-Aguilar]]></surname>
<given-names><![CDATA[Isabel A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Head and Neck Tumors Clinic Centro Médico Nacional 20 de Noviembre]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro privado de investigación Consultorio de Medicina Especializada ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>19</volume>
<numero>2</numero>
<fpage>49</fpage>
<lpage>54</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2020000200049&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2020000200049&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2020000200049&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Sorafenib was the first oral multikinase inhibitor to be approved for the treatment of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (DTC). The impact of this treatment is not known in the Mexican population.  Method: A retrospective, observational study was carried out by reviewing 31 electronic medical records of conventional treatment-refractory patients with DTC who were treated with sorafenib within the period from January 2013 to January 2018.  Results: A total of 31 patients met the inclusion criteria, with a higher frequency in women (71%), with a history of papillary DTC in 93.5%, histologic Grade I in 83.9%, and presence of vascular permeation in 67.7%. The majority of patients presented an Eastern Cooperative Oncology Group 1 at the onset of treatment (83.9%), and the most common site of metastasis was the lung in 64.5% of cases. The subjects had been previously treated with surgery (87.1%), radioiodine (74.2%), and radiotherapy (41.9%). Based on response criteria (lesion size reduction, basal thyroglobulin decrease, progression-free interval increase, tumor-associated symptoms decrease), stable disease was observed in 74.2% and an overall response rate of 25.8%. Mean progression-free survival (PFS) was 16.13 months, with a standard deviation of 2.15 months. Sorafenib was initiated at a dose of 800 mg/day, and in 30 patients (96.77%), the dose was reduced to 600 mg/day due to the presence of Grade 2 palmar-plantar erythrodysesthesia, with a mean reduction time of 11.6 weeks and, subsequently, 24 patients (80%) underwent a second dose reduction to 400 mg/day due to the presence of Grade 3 asthenia.  Conclusions: Sorafenib increased PFS, lowered thyroglobulin levels, reduced tumor size, and decreased tumor-associated symptoms in patients with locally advanced or metastatic DTC who were refractory to standard treatment. In Mexican population, due to the toxicity that occurred in the patients, the dose reduction was performed in more than half of the patients.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: El sorafenib fue el primer inhibidor oral de cinasas múltiples aprobado para el tratamiento de pacientes con cáncer de tiroides diferenciado (DTC) localmente avanzado o metastásico refractario al yodo radioactivo. El impacto de este tratamiento no se conoce en la población mexicana.  Método: Se realizó un estudio observacional retrospectivo mediante la revisión de 31 registros médicos electrónicos de pacientes con tratamiento refractario convencional con DTC que fueron tratados con sorafenib en el periodo comprendido entre enero de 2013 y enero de 2018.  Resultados: Un total de 31 pacientes cumplieron los criterios de inclusión, con mayor frecuencia de mujeres (71%), con antecedentes de DTC papilar en un 93.5%, grado histológico I en el 83.9% y presencia de permeabilidad vascular en el 67.7%. La mayoría de los pacientes presentaron una puntuación ECOG 1 al comienzo del tratamiento (83.9%) y el sitio más común de metástasis fue el pulmón (en el 64.5% de los casos). Los sujetos habían sido tratados previamente con cirugía (87.1%), radioyodo (74.2%) y radioterapia (41.9%). Según los criterios de respuesta (reducción del tamaño de la lesión, disminución de la tiroglobulina basal, aumento del intervalo libre de progresión, disminución de los síntomas asociados con el tumor), se observó una enfermedad estable en el 74.2% y una tasa del 25.8% de respuesta general. La supervivencia libre de progresión (SLP) media fue de 16.13 meses, con una desviación estándar de 2.15 meses. El sorafenib se inició con una dosis de 800 mg/día, y en 30 pacientes (96.77%) la dosis se redujo a 600 mg/día debido a la presencia de eritrodisestesia plantar de palmera grado 2, con un tiempo de reducción promedio de 11.6 semanas; posteriormente 24 pacientes (80%) se sometieron a una segunda reducción de dosis a 400 mg/día debido a la presencia de astenia de grado 3.  Conclusiones: El sorafenib aumentó la SLP, disminuyó los niveles de tiroglobulina, redujo el tamaño del tumor y disminuyó los síntomas asociados con el tumor en pacientes con DTC localmente avanzado o metastásico que eran refractarios al tratamiento estándar. En la población mexicana, debido a la toxicidad que se produjo en los pacientes, la reducción de la dosis se realizó en más de la mitad de los pacientes.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Differentiated thyroid cancer]]></kwd>
<kwd lng="en"><![CDATA[Sorafenib]]></kwd>
<kwd lng="en"><![CDATA[Tyrosine kinase inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Iodine-refractory cancer]]></kwd>
<kwd lng="es"><![CDATA[Cáncer diferenciado de tiroides]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores de la tirosina cinasa]]></kwd>
<kwd lng="es"><![CDATA[Sorafenib]]></kwd>
<kwd lng="es"><![CDATA[Cáncer refractario al yodo]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maniakas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zafereo]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thyroid disease around the world]]></article-title>
<source><![CDATA[Otolaryngol Clin North Am]]></source>
<year>2018</year>
<volume>51</volume>
<page-range>631-42</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[DeSantis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes in thyroid cancer incidence, post-2009 American Thyroid Association guidelines]]></article-title>
<source><![CDATA[Laryngoscope]]></source>
<year>2017</year>
<volume>127</volume>
<page-range>2437-41</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Board PDQATE</collab>
<article-title xml:lang=""><![CDATA[Thyroid cancer treatment (adult) (PDQ(R)):health professional version]]></article-title>
<source><![CDATA[Pdq Cancer Information Summaries]]></source>
<year>2002</year>
<publisher-loc><![CDATA[Bethesda ]]></publisher-loc>
<publisher-name><![CDATA[National Cancer Institute]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tumino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Frasca]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Newbold]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer]]></article-title>
<source><![CDATA[Front Endocrinol (Lausanne)]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>312</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Chong]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ha]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[O]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma]]></article-title>
<source><![CDATA[Clin Endocrinol (Oxf)]]></source>
<year>2017</year>
<volume>87</volume>
<page-range>73-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D'Cruz]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Vaish]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vaidya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nixon]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Vander Poorten]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular markers in well-differentiated thyroid cancer]]></article-title>
<source><![CDATA[Eur Arch Otorhinolaryngol]]></source>
<year>2018</year>
<volume>275</volume>
<page-range>1375-84.8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[Nostrand D]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radioiodine refractory differentiated thyroid cancer]]></article-title>
<source><![CDATA[Crit Rev Oncol Hematol]]></source>
<year>2018</year>
<volume>125</volume>
<page-range>111-20.0</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Iglesias]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Klain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pitoia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Schlumberger]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radioactive iodine-refractory differentiated thyroid cancer:an uncommon but challenging situation]]></article-title>
<source><![CDATA[Arch Endocrinol Metab]]></source>
<year>2017</year>
<volume>61</volume>
<page-range>81-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brose]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Smit]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Pitoia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fellous]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[DeSanctis]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Timing of multikinase inhibitor initiation in differentiated thyroid cancer]]></article-title>
<source><![CDATA[Endocr Relat Cancer]]></source>
<year>2017</year>
<volume>24</volume>
<page-range>237-42</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina-Vega]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García-Alemán]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sebastián-Ochoa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mancha-Doblas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Trigo-Pérez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Tinahones-Madueño]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer:experience in clinical practice]]></article-title>
<source><![CDATA[Endocrine]]></source>
<year>2018</year>
<volume>59</volume>
<page-range>395-401.1</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Na]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune landscape of papillary thyroid cancer and immunotherapeutic implications]]></article-title>
<source><![CDATA[Endocr Relat Cancer]]></source>
<year>2018</year>
<volume>25</volume>
<page-range>523-31</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rashid]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Mansoor]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Tabassum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aziz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Arfat]]></surname>
<given-names><![CDATA[WO]]></given-names>
</name>
<name>
<surname><![CDATA[Naoum]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Signaling cascades in thyroid cancer:increasing the armory of archers to hit bullseye]]></article-title>
<source><![CDATA[J Cell Biochem]]></source>
<year>2018</year>
<volume>119</volume>
<page-range>3798-808</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brose]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Nutting]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Jarzab]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Elisei]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Siena]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bastholt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>384</volume>
<page-range>319-28</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schlumberger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tahara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wirth]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brose]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Elisei]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lenvatinib versus placebo in radioiodine-refractory thyroid cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<page-range>621-30</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugino]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nagahama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kitagawa]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ohkuwa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Uruno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuzu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients]]></article-title>
<source><![CDATA[Endocr J]]></source>
<year>2018</year>
<volume>65</volume>
<page-range>299-306</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of tyrosine kinase inhibitors in patients with differentiated thyroid cancer:real-world use of lenvatinib and sorafenib in Korea]]></article-title>
<source><![CDATA[Front Endocrinol (Lausanne)]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>384</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment:a Korean multicenter study]]></article-title>
<source><![CDATA[Thyroid]]></source>
<year>2019</year>
<volume>29</volume>
<page-range>1804-10</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
